Johnson & Johnson Inc is to acquire all of the outstanding shares of Intra-Cellular Therapies Inc of the US in a deal that will significantly strengthen its neuroscience franchise. The transaction will be executed at $132 per share in cash for a total equity value of $14.6 billion. Announced on 13 January, the deal is the largest biotech merger since 2023, according to the Axios news website. The lead asset Caplyta (lumateperone), is an approved therapy for the treatment of adults with schizophrenia and depressive episodes associated with bipolar 1 or 2 disorder.
